Abstract

We evaluated the association between epithelial–mesenchymal transition (EMT)‐derived markers and expression of proteins associated with cell proliferation and tumor growth, as well as their prognostic roles, in 61 patients (mean age 52 ± 10 years) with locally advanced cervical cancer, all of whom were treated with chemoradiation and intracavitary brachytherapy. We used immunohistochemical analysis to assess the expression of proteins targeted in our investigation. Various statistical analyses were then conducted to assess protein marker associations with survival outcomes. Forty‐six percent of the patients were positive for human papilloma virus. Median progression‐free survival (PFS) was 6.6 months (95% confidence interval [CI]: 4.0–9.1, whereas overall survival (OS) was 30.0 months (95% CI: 11–48). Multivariate analysis demonstrated that vascular endothelial growth factor (VEGF) (P = 0.002), epidermal growth factor receptor (EGFR) (P = 0.001), and TWIST2 (P = 0.001) expression levels, as well as a tumor size <6 cm (P = 0.02), influenced OS. Changes in TWIST2 levels and loss of E‐cadherin expression were correlated with VEGF and EGFR levels; furthermore, patients with high TWIST2 expression had shorter OS (P = 0.0001), as those with loss of E‐cadherin (P = 0.02). OS was even shorter when positive EGFR or VEGF expression was related with EMT markers (positive EGFR + negative E‐cadherin: median 14 months, 95% CI: 3–24; negative EGFR + positive E‐cadherin: median 31 months, 95% CI: 14–NA; P = 0.02.). The presence of EMT markers was associated with proliferative and pro‐angiogenic protein expression and influenced the prognosis of locally advanced cervical cancer.

Highlights

  • Cervical cancer (CC) is the second leading global neoplasm in incidence and mortality

  • We describe the relationship between VEGFR and epidermal growth factor receptor (EGFR) expression and key epithelial–mesenchymal transition (EMT) markers in a population of women with CC that was treated with CRT and brachytherapy, establishing the impact over a range of outcomes

  • Regarding history of preneoplastic lesions, it was not possible to obtain data from previous screening studies in 47% of cases, and positive human papilloma virus (HPV) was documented for 28 patients

Read more

Summary

Introduction

Cervical cancer (CC) is the second leading global neoplasm in incidence and mortality. This disease causes approximately 234,000 deaths, 40,000 of which occur in developing countries [1]. Information regarding the epidemiology of the disease in Latin America is limited, CC is known to be the second most common cause of cancer-r­elated death among women from Colombia and Mexico [3, 4], where locally advanced tumors (clinical stages IB2 to IVA according to the International Federation of Gynecology and Obstetrics [FIGO] staging classification) account for 60% of cases; lesions in early. Despite the positive impact of this intervention, approximately 35% of patients progress, and it is imperative to identify factors related to the biological behavior of the disease [6]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call